Sinphar Pharmaceutical Co.,Ltd. (1734.TW)
TWD 30.9
(0.65%)
TWD 30.9
(0.65%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.49 Billion TWD | 5.55% |
| 2022 | 1.41 Billion TWD | -4.73% |
| 2021 | 1.48 Billion TWD | -1.61% |
| 2020 | 1.51 Billion TWD | 7.16% |
| 2019 | 1.4 Billion TWD | 2.0% |
| 2018 | 1.38 Billion TWD | 4.7% |
| 2017 | 1.31 Billion TWD | 8.85% |
| 2016 | 1.21 Billion TWD | 15.08% |
| 2015 | 1.05 Billion TWD | 1.36% |
| 2014 | 1.03 Billion TWD | 29.04% |
| 2013 | 805.46 Million TWD | -15.37% |
| 2012 | 951.74 Million TWD | 30.74% |
| 2011 | 727.98 Million TWD | -12.91% |
| 2010 | 835.89 Million TWD | 26.36% |
| 2009 | 661.49 Million TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 1.51 Billion TWD | 2.55% |
| 2024 Q1 | 1.48 Billion TWD | -0.86% |
| 2023 FY | 1.49 Billion TWD | 5.55% |
| 2023 Q4 | 1.49 Billion TWD | -0.3% |
| 2023 Q3 | 1.49 Billion TWD | 7.79% |
| 2023 Q1 | 1.4 Billion TWD | -0.89% |
| 2023 Q2 | 1.39 Billion TWD | -0.91% |
| 2022 Q3 | 1.52 Billion TWD | -4.53% |
| 2022 Q1 | 1.62 Billion TWD | 9.25% |
| 2022 FY | 1.41 Billion TWD | -4.73% |
| 2022 Q4 | 1.41 Billion TWD | -7.38% |
| 2022 Q2 | 1.6 Billion TWD | -1.39% |
| 2021 Q1 | 1.49 Billion TWD | -0.97% |
| 2021 Q4 | 1.48 Billion TWD | 1.37% |
| 2021 FY | 1.48 Billion TWD | -1.61% |
| 2021 Q3 | 1.46 Billion TWD | -1.0% |
| 2021 Q2 | 1.48 Billion TWD | -0.99% |
| 2020 Q3 | 1.52 Billion TWD | 8.33% |
| 2020 FY | 1.51 Billion TWD | 7.16% |
| 2020 Q4 | 1.51 Billion TWD | -0.97% |
| 2020 Q1 | 1.35 Billion TWD | -3.62% |
| 2020 Q2 | 1.4 Billion TWD | 3.64% |
| 2019 Q2 | 1.36 Billion TWD | -0.64% |
| 2019 FY | 1.4 Billion TWD | 2.0% |
| 2019 Q4 | 1.4 Billion TWD | 8.37% |
| 2019 Q3 | 1.3 Billion TWD | -4.55% |
| 2019 Q1 | 1.37 Billion TWD | -0.76% |
| 2018 Q4 | 1.38 Billion TWD | 2.91% |
| 2018 Q1 | 1.31 Billion TWD | -0.69% |
| 2018 Q2 | 1.3 Billion TWD | -0.72% |
| 2018 FY | 1.38 Billion TWD | 4.7% |
| 2018 Q3 | 1.34 Billion TWD | 3.19% |
| 2017 Q4 | 1.31 Billion TWD | 4.22% |
| 2017 FY | 1.31 Billion TWD | 8.85% |
| 2017 Q2 | 1.27 Billion TWD | 3.39% |
| 2017 Q3 | 1.26 Billion TWD | -0.59% |
| 2017 Q1 | 1.23 Billion TWD | 1.62% |
| 2016 Q1 | 1.04 Billion TWD | -0.94% |
| 2016 Q4 | 1.21 Billion TWD | -3.23% |
| 2016 Q2 | 1.21 Billion TWD | 16.25% |
| 2016 Q3 | 1.25 Billion TWD | 3.27% |
| 2016 FY | 1.21 Billion TWD | 15.08% |
| 2015 Q4 | 1.05 Billion TWD | -1.04% |
| 2015 Q3 | 1.06 Billion TWD | -1.12% |
| 2015 Q1 | 1.02 Billion TWD | -1.09% |
| 2015 Q2 | 1.07 Billion TWD | 4.72% |
| 2015 FY | 1.05 Billion TWD | 1.36% |
| 2014 Q2 | 1.18 Billion TWD | 9.3% |
| 2014 Q3 | 1.2 Billion TWD | 1.56% |
| 2014 FY | 1.03 Billion TWD | 29.04% |
| 2014 Q4 | 1.03 Billion TWD | -13.45% |
| 2014 Q1 | 1.08 Billion TWD | 34.3% |
| 2013 Q4 | 805.46 Million TWD | 13.99% |
| 2013 FY | 805.46 Million TWD | -15.37% |
| 2013 Q2 | 976.7 Million TWD | 3.75% |
| 2013 Q1 | 941.38 Million TWD | -1.09% |
| 2013 Q3 | 706.6 Million TWD | -27.65% |
| 2012 Q2 | 795.9 Million TWD | 11.02% |
| 2012 FY | 951.74 Million TWD | 30.74% |
| 2012 Q1 | 716.88 Million TWD | -1.52% |
| 2012 Q3 | 975.65 Million TWD | 22.58% |
| 2012 Q4 | 951.74 Million TWD | -2.45% |
| 2011 Q4 | 727.98 Million TWD | 78.72% |
| 2011 Q1 | 878.11 Million TWD | 5.05% |
| 2011 Q2 | 790.3 Million TWD | -10.0% |
| 2011 FY | 727.98 Million TWD | -12.91% |
| 2011 Q3 | 407.34 Million TWD | -48.46% |
| 2010 Q4 | 835.89 Million TWD | 0.0% |
| 2010 FY | 835.89 Million TWD | 26.36% |
| 2009 FY | 661.49 Million TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Apex Biotechnology Corp. | 116.19 Million TWD | -1185.881% |
| Panion & Bf Biotech Inc. | 125.41 Million TWD | -1091.33% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 700 Million TWD | -113.449% |
| GenMont Biotech Incorporation | 20.11 Million TWD | -7329.107% |
| Abnova (Taiwan) Corporation | 2.6 Million TWD | -57344.906% |
| Adimmune Corporation | 1.91 Billion TWD | 22.099% |
| Tanvex BioPharma, Inc. | 1.56 Billion TWD | 4.731% |
| Polaris Group | 352.96 Million TWD | -323.307% |
| Energenesis Biomedical CO.,LTD. | - TWD | -Infinity% |
| UnicoCell Biomed Co., Ltd. | 68.23 Million TWD | -2089.668% |
| PELL Bio-Med Technology Co. Ltd. | 147.46 Million TWD | -913.204% |